Search results for: Precision Medicine
Filter search results
What do Pharmaceuticals Really Cost in the Long Run?
6 October 2017
…OHE’s collaboration with Darius Lakdawalla (University of Southern California), Joanna MacEwan (Precision Health Economics), Robert Dubois (National Pharmaceutical Council) and Kimberly Westrich (National Pharmaceutical Council). The policy debate over…
The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’
3 December 2020
Bernarda Zamora presented at the virtual event entitled ‘Value of Diagnostic Information in Heart Failure’, which was organised by Roche Diagnostics. The panel, composed of six experts representing a range…
Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.
12 April 2016
…topic of the economics of the market for medicines. The first half of the lecture included an overview of the global challenges facing medicines manufacturers, discussion of the ‘supply side’…
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions
1 January 2020
…ethical and economic challenges faced by medicines for ultra-rare conditions, with particular reference… In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised…
Drivers of the Growth in Medicines Expenditure
1 October 1997
Increases in expenditure on medicines, above the level of increases in health care expenditure generally, are a feature of all Western health systems, including the UK’s. This paper examines the…
The Doctor’s (Ethical and Economic) Dilemma
1 August 1996
In this OHE lecture Professor Sackett sets out a compelling case for evidence-based medicine to be at the core of a comprehensive, tax-funded NHS that enjoys the confidence of the…
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
1 December 2021
…still surround the effectiveness or cost-effectiveness of a new medicine, making it difficult to agree on a medicine’s price. One solution to avoid unduly delaying or restricting patients’ access is…
Priscila Radu
20 September 2021
Priscila has published research on various health economics topics, including changes in HTA methods in several regions, assessment pathways for precision oncology, and regulatory landscape of digital health in the…
Insights From 2022 and Emerging Issues in 2023
7 December 2022, 12:00am
…of health outcomes and where we have got to in including carers’ quality of life in Health Technology evaluations. Innovation, precision and value: Showcasing OHE’s indication-based payment masterclass and demonstrating…